secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-149623
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology appoints permanent CEO, new CFO and COO; Muntner gets stock option inducement
--------------------------------------------------------------------------------

- Mani Mohindru promoted from interim to President & CEO; base salary $655K, $100K bonus plus 55% discretionary.
- Josh Muntner named CFO effective April 6, 2026; base salary $475K, 40% bonus; granted options to buy 486,650 shares at $1.58.
- Ajay Aggarwal appointed COO effective April 27, 2026; base salary $490K, 40% bonus; expects 400,000 stock options.
- Muntner has 25+ years biopharma finance experience, previously CFO at Imvax and Mesoblast, raised over $300M combined.
- Dr. Aggarwal brings 15+ years pharma experience, most recently SVP Clinical Development at Aclaris Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526149623/0001193125-26-149623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526149623/crdf-20260406.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-149623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer